Latest Covid Study Pause Puts Stock Rallies at Risk for Other Vaccine Makers

(Bloomberg) -- Study and trial pauses can be a standard operating procedure in drug development, yet it could put the triple- and quadruple-digit rallies for some biotechs at risk.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.